All AbMole products are for research use only, cannot be used for human consumption.
BIRB 796 (Doramapimod) is a protein kinase inhibitor of p38 MAPK. BIRB 796 (Doramapimod) has high picomolar affinity (Kd = 100 pM) for p38 MAP kinase and low nanomolar inhibitory activity (IC50 = 18 nM) against TNFα in THP-1 cell culture. The p38 inhibitor BIRB 796 (Doramapimod) binds tightly (Kd = 40 nM) to ABL (T315I) and inhibits the BMS-354825- and imatinib-resistant ABL (T315I) kinase.
Cell Signal. 2024 Jan ;8;115:111040.
MBIP promotes ESCC metastasis by activating MAPK pathway
BIRB796 purchased from AbMole
 |
Source | PLoS One (2013). Figure 4. BIRB796 |
| Method | Western blot | |
| Cell Lines | MDR cells | |
| Concentrations | 10 μM | |
| Incubation Time | 72 h | |
| Results | These data indicated that BIRB796 mediated the reversal of MDR by inhibiting the function of ABCB1, and not due to inhibition of ABCB1 expression. |
| Cell Experiment | |
|---|---|
| Cell lines | MM derived cell line |
| Preparation method | Growth inhibition assay. The growth inhibitory effect of BIRB 796 on MM cell line growth was assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT, Sigma Chem-ical) dye absorbance, as previously described (Yasui et al,2005a) |
| Concentrations | 0, 100, 400nM |
| Incubation time | 72h |
| Animal Experiment | |
|---|---|
| Animal models | Male Crlj:CD1(ICR)mice |
| Formulation | saline |
| Dosages | 250, 500 or 1000 mg/kg |
| Administration | oral |
| Molecular Weight | 527.66 |
| Formula | C31H37N5O3 |
| CAS Number | 285983-48-4 |
| Solubility (25°C) | DMSO 66 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related p38 MAPK Products |
|---|
| SSK1
SSK1 is a senescence-specific killing compound and is a precursor for β-galactosidase, which can reduce the inflammatory response. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, promote mitochondrial DNA damage and selectively killed senescent cells. |
| p38 MAP Kinase Inhibitor III
p38 MAP Kinase Inhibitor III is a p38 MAPK inhibitor with an IC50 of 0.9 μM. p38 MAP Kinase Inhibitor III also inhibits IL-1β and TNF-α release with IC50 values of 0.37 μM and 0.044 μM, respectively. |
| (R)-STU104
(R)-STU104 is a potent and orally active TAK1-MKK3 interaction inhibitor with IC50s of 0.58 μM and 4.0 μM for TNF-α and MKK3 phosphorylation. |
| SB 706504
SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD). |
| RWJ-67657
RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
